Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Spruce Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Spruce Biosciences, Inc.’s stock price such as:

• Spruce Biosciences, Inc.’s current stock price and volume
• Why Spruce Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for SPRB from analysts
• SPRB’s stock price momentum as measured by its relative strength

About Spruce Biosciences, Inc. (SPRB)

Before we jump into Spruce Biosciences, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Want to learn more about Spruce Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Spruce Biosciences, Inc..

Spruce Biosciences, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Spruce Biosciences, Inc.’s stock price was $42.830.

Spruce Biosciences, Inc. is down 1.25% from its previous closing price of $43.370.

During the last market session, Spruce Biosciences, Inc.’s stock traded between $42.000 and $43.300. Currently, there are approximately 1.37 million shares outstanding for Spruce Biosciences, Inc..

Spruce Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Spruce Biosciences, Inc. Stock Price History

Spruce Biosciences, Inc.’s (SPRB) price is currently down 20.69% so far this month.

During the month of July, Spruce Biosciences, Inc.’s stock price has reached a high of $55.210 and a low of $40.325.

Over the last year, Spruce Biosciences, Inc. has hit prices as high as $240.000 and as low as $7.000. Year to date, Spruce Biosciences, Inc.’s stock is down 50.83%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Spruce Biosciences, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Spruce Biosciences, Inc.’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Spruce Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Spruce Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Spruce Biosciences, Inc. (SPRB) by visiting AAII Stock Evaluator.

Relative Price Strength of Spruce Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Spruce Biosciences, Inc. has a weighted four-quarter relative price strength of 219.00%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Spruce Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Spruce Biosciences, Inc. Stock Price: Bottom Line

As of July 31, 2026, Spruce Biosciences, Inc.’s stock price is $42.830, which is down 1.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Spruce Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.